Download PDF
Semin Respir Crit Care Med 2020; 41(01): 080-098
DOI: 10.1055/s-0039-3401990
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Invasive Pulmonary Aspergillosis

Marie-Pierre Ledoux
1   Department of Oncology and Hematology, University Hospital of Strasbourg, Strasbourg, France
,
Blandine Guffroy
1   Department of Oncology and Hematology, University Hospital of Strasbourg, Strasbourg, France
,
Yasmine Nivoix
2   Department of Pharmacy, University Hospital of Strasbourg, Strasbourg, France
,
Célestine Simand
1   Department of Oncology and Hematology, University Hospital of Strasbourg, Strasbourg, France
,
Raoul Herbrecht
1   Department of Oncology and Hematology, University Hospital of Strasbourg, Strasbourg, France
3   Interface Recherche Fondamentale et Appliquée en Cancérologie, Université de Strasbourg, Inserm, UMR-S1113/IRFAC, Strasbourg, France
› Author Affiliations
Further Information

Publication History

Publication Date:
30 January 2020 (online)

    Permissions and Reprints

Abstract

Invasive pulmonary aspergillosis (IPA) remains difficult to diagnose and to treat. Most common risk factors are prolonged neutropenia, hematopoietic stem cell or solid organ transplantation, inherited or acquired immunodeficiency, administration of steroids or other immunosuppressive agents including monoclonal antibodies and new small molecules used for cancer therapy. Critically ill patients are also at high risk of IPA. Clinical signs are unspecific. Early computed tomography (CT)-scan identifies the two main aspects, angioinvasive and airway invasive aspergillosis. Although CT-scan findings are not fully specific they usually allow early initiation of therapy before mycological confirmation of the diagnosis. Role of 18F-fludeoxyglucose positron emission tomography with computed tomography (18F-FDG PET/CT) is discussed. Confirmation is based on microscopy and culture of respiratory samples, histopathology in case of biopsy, and importantly by detection of Aspergillus galactomannan using an immunoassay in serum and bronchoalveolar lavage fluid. Deoxyribonucleic acid detection by polymerase chain reaction is now standardized and increases the diagnosis yield. Two point of care tests detecting an Aspergillus glycoprotein using a lateral flow assay are also available. Mycological results allow classification into proven (irrespective of underlying condition), probable or possible (for cancer and severely immunosuppressed patients) or putative (for critically ill patients) IPA. New antifungal agents have been developed over the last 2 decades: new azoles (voriconazole, posaconazole, isavuconazole), lipid formulations of amphotericin B (liposomal amphotericin B, amphotericin B lipid complex), echinocandins (caspofungin, micafungin, anidulafungin). Results of main trials assessing these agents in monotherapy or in combination are presented as well as the recommendations for their use according to international guidelines. New agents are under development.

Keywords

Aspergillus fumigatus - tracheobronchial aspergillosis - voriconazole - Isavuconazole - posaconazole - combination therapy - review - galactomannan - acute myeloblastic leukemia - allogeneic hematopoietic stem cell transplantation - solid organ transplantation
 

  • References

  • 1 Schweer KE, Jakob B, Liss B. , et al. Domestic mould exposure and invasive aspergillosis-air sampling of Aspergillus spp. spores in homes of hematological patients, a pilot study. Med Mycol 2016; 54 (06) 576-583
    CrossrefPubMedGoogle Scholar
  • 2 Rüping MJ, Gerlach S, Fischer G. , et al. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study. J Hosp Infect 2011; 78 (03) 226-230
    CrossrefPubMedGoogle Scholar
  • 3 Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment—rethinking our approach to prevention. Clin Infect Dis 2001; 33 (09) 1549-1552
    CrossrefPubMedGoogle Scholar
  • 4 Peláez T, Muñoz P, Guinea J. , et al. Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. Clin Infect Dis 2012; 54 (03) e24-e31
    CrossrefPubMedGoogle Scholar
  • 5 Panackal AA, Li H, Kontoyiannis DP. , et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010; 50 (12) 1588-1597
    CrossrefPubMedGoogle Scholar
  • 6 Viscoli C, Castagnola E. Geoclimatic factors and invasive aspergillosis after allogeneic hematopoietic stem cell transplantation: new perspectives for patient management?. Clin Infect Dis 2010; 50 (12) 1598-1600
    CrossrefPubMedGoogle Scholar
  • 7 Sessa A, Meroni M, Battini G. , et al. Nosocomial outbreak of Aspergillus fumigatus infection among patients in a renal unit?. Nephrol Dial Transplant 1996; 11 (07) 1322-1324
    CrossrefPubMedGoogle Scholar
  • 8 Muñoz P, Guinea J, Peláez T, Durán C, Blanco JL, Bouza E. Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the HEPA air filtration system. Transpl Infect Dis 2004; 6 (01) 50-54
    CrossrefPubMedGoogle Scholar
  • 9 Pegues DA, Lasker BA, McNeil MM, Hamm PM, Lundal JL, Kubak BM. Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of person-to-person airborne transmission. Clin Infect Dis 2002; 34 (03) 412-416
    CrossrefPubMedGoogle Scholar
  • 10 Walsh TJ, Roilides E, Cortez K, Kottilil S, Bailey J, Lyman CA. Control, immunoregulation, and expression of innate pulmonary host defenses against Aspergillus fumigatus . Med Mycol 2005; 43 (Suppl. 01) S165-S172
    CrossrefPubMedGoogle Scholar
  • 11 Mackel JJ, Steele C. Host defense mechanisms against Aspergillus fumigatus lung colonization and invasion. Curr Opin Microbiol 2019; 52: 14-19
    CrossrefPubMedGoogle Scholar
  • 12 Ellett F, Jorgensen J, Frydman GH, Jones CN, Irimia D. Neutrophil interactions stimulate evasive hyphal branching by Aspergillus fumigatus . PLoS Pathog 2017; 13 (01) e1006154
    CrossrefPubMedGoogle Scholar
  • 13 Tavakoli M, Yazdani Charati J, Hedayati MT. , et al. National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis. Expert Rev Respir Med 2019; 13 (11) 1121-1134
    CrossrefPubMedGoogle Scholar
  • 14 Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR. Invasive aspergillosis in developing countries. Med Mycol 2011; 49 (Suppl. 01) S35-S47
    CrossrefPubMedGoogle Scholar
  • 15 Lamoth F. Aspergillus fumigatus-related species in clinical practice. Front Microbiol 2016; 7: 683
    PubMedGoogle Scholar
  • 16 Fernandez-Molina JV, Abad-Diaz-de-Cerio A, Sueiro-Olivares M. , et al. Rapid and specific detection of section Fumigati and Aspergillus fumigatus in human samples using a new multiplex real-time PCR. Diagn Microbiol Infect Dis 2014; 80 (02) 111-118
    CrossrefPubMedGoogle Scholar
  • 17 Hubka V, Kubatova A, Mallatova N. , et al. Rare and new etiological agents revealed among 178 clinical Aspergillus strains obtained from Czech patients and characterized by molecular sequencing. Med Mycol 2012; 50 (06) 601-610
    CrossrefPubMedGoogle Scholar
  • 18 Walsh TJ, Wissel MC, Grantham KJ. , et al. Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis. J Clin Microbiol 2011; 49 (12) 4150-4157
    CrossrefPubMedGoogle Scholar
  • 19 Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017; 3 (04) 3
    PubMedGoogle Scholar
  • 20 Denning DW, Cadranel J, Beigelman-Aubry C. , et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47 (01) 45-68
    CrossrefPubMedGoogle Scholar
  • 21 Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol 2009; 47 (Suppl. 01) S271-S281
    CrossrefPubMedGoogle Scholar
  • 22 Kontoyiannis DP, Marr KA, Park BJ. , et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50 (08) 1091-1100
    CrossrefPubMedGoogle Scholar
  • 23 Kolwijck E, van de Veerdonk FL. The potential impact of the pulmonary microbiome on immunopathogenesis of Aspergillus-related lung disease. Eur J Immunol 2014; 44 (11) 3156-3165
    CrossrefPubMedGoogle Scholar
  • 24 Delsuc C, Cottereau A, Frealle E. , et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study. Crit Care 2015; 19: 421
    CrossrefPubMedGoogle Scholar
  • 25 Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect 2019; (e-pub ahead of print). DOI: 10.1016/j.cmi.2019.04.031.
    CrossrefPubMedGoogle Scholar
  • 26 Briard B, Mislin GLA, Latgé JP, Beauvais A. Interactions between Aspergillus fumigatus and pulmonary bacteria: current state of the field, new data, and future perspective. J Fungi (Basel) 2019; 5 (02) 5
    PubMedGoogle Scholar
  • 27 Sass G, Nazik H, Penner J. , et al. Aspergillus-Pseudomonas interaction, relevant to competition in airways. Med Mycol 2019; 57 (Supplement_2): S228-S232
    CrossrefPubMedGoogle Scholar
  • 28 van de Peppel RJ, Visser LG, Dekkers OM, de Boer MGJ. The burden of invasive aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review. J Infect 2018; 76 (06) 550-562
    CrossrefPubMedGoogle Scholar
  • 29 Zilberberg MD, Nathanson BH, Harrington R, Spalding JR, Shorr AF. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009–2013. Clin Infect Dis 2018; 67 (05) 727-735
    CrossrefPubMedGoogle Scholar
  • 30 Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal Infection in a US Health Care Network. Open Forum Infect Dis 2018; 5 (08) ofy187
    CrossrefPubMedGoogle Scholar
  • 31 Girmenia C. New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. F1000 Res 2019; 8: 8
    CrossrefPubMedGoogle Scholar
  • 32 Herbrecht R, Natarajan-Amé S, Letscher-Bru V, Canuet M. Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 2004; 25 (02) 191-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 2012; 1272: 23-30
    CrossrefPubMedGoogle Scholar
  • 34 Jain S, Kapoor G. Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center. J Pediatr Hematol Oncol 2015; 37 (01) e1-e5
    CrossrefPubMedGoogle Scholar
  • 35 Lestrade PP, van der Velden WJFM, Bouwman F. , et al. Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. J Antimicrob Chemother 2018; 73 (05) 1389-1394
    CrossrefPubMedGoogle Scholar
  • 36 Cordonnier C, Pautas C, Maury S. , et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48 (08) 1042-1051
    CrossrefPubMedGoogle Scholar
  • 37 Avcu G, Karapinar DY, Akinci AB. , et al. Utility of the serum galactomannan assay for the diagnosis of invasive aspergillosis in children with acute lymphoblastic leukemia. Int J Infect Dis 2017; 54: 8-12
    CrossrefPubMedGoogle Scholar
  • 38 Mariette C, Tavernier E, Hocquet D. , et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma 2017; 58 (03) 586-593
    CrossrefPubMedGoogle Scholar
  • 39 Pomares H, Arnan M, Sánchez-Ortega I, Sureda A, Duarte RF. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?. Mycoses 2016; 59 (08) 516-519
    CrossrefPubMedGoogle Scholar
  • 40 Falantes JF, Calderón C, Márquez-Malaver FJ. , et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 2014; 14 (01) 80-86
    CrossrefPubMedGoogle Scholar
  • 41 Cornely OA, Maertens J, Winston DJ. , et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (04) 348-359
    CrossrefPubMedGoogle Scholar
  • 42 Ullmann AJ, Lipton JH, Vesole DH. , et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (04) 335-347
    CrossrefPubMedGoogle Scholar
  • 43 Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis 2014; 59 (Suppl. 05) S360-S364
    CrossrefPubMedGoogle Scholar
  • 44 Enblad G, Hagberg H, Erlanson M. , et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103 (08) 2920-2924
    CrossrefPubMedGoogle Scholar
  • 45 Gallamini A, Zaja F, Patti C. , et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110 (07) 2316-2323
    CrossrefPubMedGoogle Scholar
  • 46 Anoop P, Stanford M, Saso R, Dearden CE. Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia. J Infect Chemother 2010; 16 (02) 150-151
    CrossrefPubMedGoogle Scholar
  • 47 Karia S, Jeyapalan K, Kennedy B. Aspergillus fumigatus osteomyelitis in a patient receiving alemtuzumab for B-cell chronic lymphocytic leukaemia. Br J Haematol 2011; 153 (02) 147
    CrossrefPubMedGoogle Scholar
  • 48 Gibbs SD, Herbert KE, McCormack C, Seymour JF, Prince HM. Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome. Eur J Haematol 2004; 73 (06) 447-449
    CrossrefPubMedGoogle Scholar
  • 49 Ghez D, Calleja A, Protin C. , et al; French Innovative Leukemia Organization (FILO) CLL group. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 2018; 131 (17) 1955-1959
    CrossrefPubMedGoogle Scholar
  • 50 Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol 2009; 26 (03) 175-183
    CrossrefPubMedGoogle Scholar
  • 51 Lundin J, Hagberg H, Repp R. , et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101 (11) 4267-4272
    CrossrefPubMedGoogle Scholar
  • 52 Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 2009; 43 (02) 121-126
    CrossrefPubMedGoogle Scholar
  • 53 Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis 2018; 66 (01) 140-148
    CrossrefPubMedGoogle Scholar
  • 54 Mellinghoff SC, Panse J, Alakel N. , et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 2018; 97 (02) 197-207
    CrossrefPubMedGoogle Scholar
  • 55 Nivoix Y, Ledoux MP, Herbrecht R. Antifungal therapy, new and evolving therapies. Semin Respir Crit Care Med 2020 . In press
    PubMedGoogle Scholar
  • 56 Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175 (06) 1459-1466
    CrossrefPubMedGoogle Scholar
  • 57 Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100 (13) 4358-4366
    CrossrefPubMedGoogle Scholar
  • 58 Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34 (07) 909-917
    CrossrefPubMedGoogle Scholar
  • 59 Montesinos P, Rodríguez-Veiga R, Boluda B. , et al. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. Bone Marrow Transplant 2015; 50 (11) 1465-1472
    CrossrefPubMedGoogle Scholar
  • 60 Robin C, Cordonnier C, Sitbon K. , et al; SAIF (Surveillance des Aspergilloses Invasives en France) and the SFGM-TC (Société Francophone de Greffe de Moelle et de Thérapie Cellulaire) Aspergillus Group. Mainly post-transplant factors are associated with invasive aspergillosis after allogeneic stem cell transplantation: a study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2019; 25 (02) 354-361
    CrossrefPubMedGoogle Scholar
  • 61 Mikulska M, Raiola AM, Bruno B. , et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44 (06) 361-370
    CrossrefPubMedGoogle Scholar
  • 62 Labbé AC, Su SH, Laverdière M. , et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007; 13 (10) 1192-1200
    CrossrefPubMedGoogle Scholar
  • 63 Pagano L, Caira M, Nosari A. , et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45 (09) 1161-1170
    CrossrefPubMedGoogle Scholar
  • 64 Pappas PG, Alexander BD, Andes DR. , et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (08) 1101-1111
    CrossrefPubMedGoogle Scholar
  • 65 Neofytos D, Fishman JA, Horn D. , et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12 (03) 220-229
    CrossrefPubMedGoogle Scholar
  • 66 Neofytos D, Chatzis O, Nasioudis D. , et al; Swiss Transplant Cohort Study. Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study. Transpl Infect Dis 2018; 20 (04) e12898
    CrossrefPubMedGoogle Scholar
  • 67 Nunley DR, Ohori P, Grgurich WF. , et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114 (05) 1321-1329
    CrossrefPubMedGoogle Scholar
  • 68 Luong ML, Chaparro C, Stephenson A. , et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014; 97 (03) 351-357
    CrossrefPubMedGoogle Scholar
  • 69 Husain S, Bhaskaran A, Rotstein C. , et al. A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture. J Heart Lung Transplant 2018; 37 (07) 886-894
    CrossrefPubMedGoogle Scholar
  • 70 Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33 (09) e13544
    PubMedGoogle Scholar
  • 71 Dandachi D, Wilson Dib R, Fernández-Cruz A. , et al. Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes. Ann Med 2018; 50 (08) 713-720
    CrossrefPubMedGoogle Scholar
  • 72 Yan X, Li M, Jiang M, Zou LQ, Luo F, Jiang Y. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer 2009; 115 (21) 5018-5025
    CrossrefPubMedGoogle Scholar
  • 73 Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117 (04) e711-e716
    CrossrefPubMedGoogle Scholar
  • 74 Bartlett AW, Cann MP, Yeoh DK. , et al. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. Pediatr Blood Cancer 2019; 66 (04) e27564
    CrossrefPubMedGoogle Scholar
  • 75 Park S, Park S, Choi H. , et al. Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib. Korean J Intern Med (Korean Assoc Intern Med) 2018; 33 (01) 211-213
    CrossrefPubMedGoogle Scholar
  • 76 Williams J, Lim R, Tambyah P. Invasive aspergillosis associated with bevacizumab, a vascular endothelial growth factor inhibitor. Int J Infect Dis 2007; 11 (06) 549-550
    CrossrefPubMedGoogle Scholar
  • 77 Johnson DH, Fehrenbacher L, Novotny WF. , et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
    CrossrefPubMedGoogle Scholar
  • 78 Inthasot V, Bruyneel M, Muylle I, Ninane V. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases. Acta Clin Belg 2019; (e-pub ahead of print). DOI: 10.1080/17843286.2019.1629078.
    CrossrefPubMedGoogle Scholar
  • 79 Oltolini C, Ripa M, Andolina A. , et al. Invasive pulmonary aspergillosis complicated by carbapenem-resistant Pseudomonas aeruginosa infection during pembrolizumab immunotherapy for metastatic lung adenocarcinoma: case report and review of the literature. Mycopathologia 2019; 184 (01) 181-185
    CrossrefPubMedGoogle Scholar
  • 80 Iijima Y, Fujioka N, Uchida Y. , et al. Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: a case report. Int J Infect Dis 2018; 69: 75-77
    CrossrefPubMedGoogle Scholar
  • 81 Uchida N, Fujita K, Nakatani K, Mio T. Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab. Respirol Case Rep 2017; 6 (02) e00289
    PubMedGoogle Scholar
  • 82 Ward MJ, Davies D. Pulmonary aspergilloma after radiation therapy. Br J Dis Chest 1982; 76 (04) 361-364
    CrossrefPubMedGoogle Scholar
  • 83 Ogawa Y, Nishiyama N, Hagiwara A. , et al. A case of laryngeal aspergillosis following radiation therapy. Auris Nasus Larynx 2002; 29 (01) 73-76
    CrossrefPubMedGoogle Scholar
  • 84 Beust L, Godey B, Le Gall F, Grollier R, Le Clech G. Primary aspergillosis of the larynx and squamous cell carcinoma. Ann Otol Rhinol Laryngol 1998; 107 (10 Pt 1): 851-854
    CrossrefPubMedGoogle Scholar
  • 85 Huang HD, Li Q, Huang Y. , et al. Pseudomembranous necrotizing tracheobronchial aspergillosis: an analysis of 16 cases. Chin Med J (Engl) 2012; 125 (07) 1236-1241
    PubMedGoogle Scholar
  • 86 Huang G, Ye X, Yang X. , et al. Invasive pulmonary aspergillosis secondary to microwave ablation: a multicenter retrospective study. Int J Hyperthermia 2018; 35 (01) 71-78
    CrossrefPubMedGoogle Scholar
  • 87 Warris A, Bjørneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344 (14) 1099-1100
    CrossrefPubMedGoogle Scholar
  • 88 De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?. Infect Control Hosp Epidemiol 2003; 24 (07) 477-482
    CrossrefPubMedGoogle Scholar
  • 89 Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 2007; 86 (03) 225-226
    CrossrefPubMedGoogle Scholar
  • 90 Vallabhaneni S, Chiller TM. Fungal infections and new biologic therapies. Curr Rheumatol Rep 2016; 18 (05) 29
    CrossrefPubMedGoogle Scholar
  • 91 Streif W, Escuriola Ettingshausen C, Linde R, Kropshofer G, Zimmerhackl LB, Kreuz W. Inhibitor treatment by rituximab in congenital haemophilia A—two case reports. Hamostaseologie 2009; 29 (02) 151-154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 92 Vellanki VS, Bargman JM. Aspergillus niger peritonitis in a peritoneal dialysis patient treated with eculizumab. Ren Fail 2014; 36 (04) 631-633
    CrossrefPubMedGoogle Scholar
  • 93 Şeyhoğlu E, Erden A, Kılıç L. , et al. Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis. Eur J Rheumatol 2018; 5 (01) 75-78
    CrossrefPubMedGoogle Scholar
  • 94 Tsubouchi H, Tsuchida S, Yanagi S. , et al. Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection. Respir Med Case Rep 2019; 28: 100875
    PubMedGoogle Scholar
  • 95 Hung ML, Liao HT, Chen WS. , et al. Invasive aspergillosis in patients with systemic lupus erythematosus: a retrospective study on clinical characteristics and risk factors for mortality. Lupus 2018; 27 (12) 1944-1952
    CrossrefPubMedGoogle Scholar
  • 96 Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36 (01) 8-27
    CrossrefPubMedGoogle Scholar
  • 97 Blot SI, Taccone FS, Van den Abeele AM. , et al; AspICU Study Investigators. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186 (01) 56-64
    CrossrefPubMedGoogle Scholar
  • 98 Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 2007; 33 (10) 1694-1703
    CrossrefPubMedGoogle Scholar
  • 99 Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis 2017; 17 (11) e344-e356
    CrossrefPubMedGoogle Scholar
  • 100 Zhang X, Yang M, Hu J, Zhao H, Li L. Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: clinical presentation, risk factors, and outcomes. J Int Med Res 2018; 46 (02) 819-827
    PubMedGoogle Scholar
  • 101 Tutar N, Metan G, Koç AN. , et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8 (01) 59
    CrossrefPubMedGoogle Scholar
  • 102 Wauters J, Baar I, Meersseman P. , et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 2012; 38 (11) 1761-1768
    CrossrefPubMedGoogle Scholar
  • 103 Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M. Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis 2013; 13: 29
    CrossrefPubMedGoogle Scholar
  • 104 Schauwvlieghe AFAD, Rijnders BJA, Philips N. , et al; Dutch-Belgian Mycosis study group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6 (10) 782-792
    CrossrefPubMedGoogle Scholar
  • 105 Bassetti M, Righi E, De Pascale G. , et al. How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care 2014; 18 (04) 458
    CrossrefPubMedGoogle Scholar
  • 106 Shah MM, Hsiao EI, Kirsch CM, Gohil A, Narasimhan S, Stevens DA. Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature. Diagn Microbiol Infect Dis 2018; 91 (02) 147-152
    CrossrefPubMedGoogle Scholar
  • 107 Lahmer T, Brandl A, Rasch S. , et al. Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: an observational study. Sci Rep 2019; 9 (01) 11919
    CrossrefPubMedGoogle Scholar
  • 108 Tejerina EE, Abril E, Padilla R. , et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses 2019; 62 (08) 673-679
    CrossrefPubMedGoogle Scholar
  • 109 Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol 2011; 49 (04) 406-413
    CrossrefPubMedGoogle Scholar
  • 110 Levesque E, Ait-Ammar N, Dudau D. , et al. Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience. Ann Intensive Care 2019; 9 (01) 31
    CrossrefPubMedGoogle Scholar
  • 111 Ku YH, Chan KS, Yang CC, Tan CK, Chuang YC, Yu WL. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc 2017; 116 (09) 660-670
    CrossrefPubMedGoogle Scholar
  • 112 Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med 2007; 33 (10) 1679-1681
    CrossrefPubMedGoogle Scholar
  • 113 Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004; 56 (04) 269-276
    CrossrefPubMedGoogle Scholar
  • 114 Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Immunoparalysis as a cause for invasive aspergillosis?. Intensive Care Med 2003; 29 (11) 2068-2071
    CrossrefPubMedGoogle Scholar
  • 115 Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45 (02) 205-216
    CrossrefPubMedGoogle Scholar
  • 116 Chen X, Yu Z, Qian Y. , et al. Clinical features of fatal severe fever with thrombocytopenia syndrome that is complicated by invasive pulmonary aspergillosis. J Infect Chemother 2018; 24 (06) 422-427
    CrossrefPubMedGoogle Scholar
  • 117 Bae S, Hwang HJ, Kim MY. , et al. Invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome. Clin Infect Dis 2019; (e-pub ahead of print). DOI: 10.1093/cid/ciz673.
    CrossrefPubMedGoogle Scholar
  • 118 Tran XC, Yun Y, Van An L. , et al. Endemic severe fever with thrombocytopenia syndrome, Vietnam. Emerg Infect Dis 2019; 25 (05) 1029-1031
    CrossrefPubMedGoogle Scholar
  • 119 Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci 2012; 1272: 31-39
    CrossrefPubMedGoogle Scholar
  • 120 Kaur R, Mehra B, Dhakad MS, Goyal R, Bhalla P, Dewan R. Fungal opportunistic pneumonias in HIV/AIDS patients: an Indian tertiary care experience. J Clin Diagn Res 2017; 11 (02) DC14-DC19
    PubMedGoogle Scholar
  • 121 Holding KJ, Dworkin MS, Wan PC. , et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and adolescent spectrum of HIV disease project. Clin Infect Dis 2000; 31 (05) 1253-1257
    CrossrefPubMedGoogle Scholar
  • 122 Denis B, Guiguet M, de Castro N. , et al; French Hospital Database on HIV National Agency for Research on AIDS and Viral Hepatitis, France CO4. Relevance of EORTC criteria for the diagnosis of invasive aspergillosis in HIV-infected patients, and survival trends over a 20-year period in France. Clin Infect Dis 2015; 61 (08) 1273-1280
    CrossrefPubMedGoogle Scholar
  • 123 Pupaibool J, Limper AH. Other HIV-associated pneumonias. Clin Chest Med 2013; 34 (02) 243-254
    CrossrefPubMedGoogle Scholar
  • 124 Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998; 114 (01) 251-262
    CrossrefPubMedGoogle Scholar
  • 125 Roos D. Chronic granulomatous disease. Br Med Bull 2016; 118 (01) 50-63
    CrossrefPubMedGoogle Scholar
  • 126 Ben-Ari J, Wolach O, Gavrieli R, Wolach B. Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression. Expert Rev Anti Infect Ther 2012; 10 (08) 881-894
    CrossrefPubMedGoogle Scholar
  • 127 Beauté J, Obenga G, Le Mignot L. , et al; French PID Study Group CEREDIH. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011; 30 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 128 Blumental S, Mouy R, Mahlaoui N. , et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011; 53 (12) e159-e169
    CrossrefPubMedGoogle Scholar
  • 129 Bochud PY, Chien JW, Marr KA. , et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359 (17) 1766-1777
    CrossrefPubMedGoogle Scholar
  • 130 Sainz J, Salas-Alvarado I, López-Fernández E. , et al. TNFR1 mRNA expression level and TNFR1 gene polymorphisms are predictive markers for susceptibility to develop invasive pulmonary aspergillosis. Int J Immunopathol Pharmacol 2010; 23 (02) 423-436
    CrossrefPubMedGoogle Scholar
  • 131 Lambourne J, Agranoff D, Herbrecht R. , et al. Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2009; 49 (10) 1486-1491
    CrossrefPubMedGoogle Scholar
  • 132 Caira M, Mancinelli M, Leone G, Pagano L. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med Mycol 2011; 49 (Suppl. 01) S13-S16
    CrossrefPubMedGoogle Scholar
  • 133 Sainz J, Hassan L, Perez E. , et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007; 109 (01) 76-82
    CrossrefPubMedGoogle Scholar
  • 134 Sainz J, Lupiáñez CB, Segura-Catena J. , et al. Dectin-1 and DC-SIGN polymorphisms associated with invasive pulmonary Aspergillosis infection. PLoS One 2012; 7 (02) e32273
    CrossrefPubMedGoogle Scholar
  • 135 White PL, Parr C, Barnes RA. Predicting invasive aspergillosis in hematology patients by combining clinical and genetic risk factors with early diagnostic biomarkers. J Clin Microbiol 2017; 56 (01) e01122-e17
    PubMedGoogle Scholar
  • 136 Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 2009; 15 (07) 625-633
    CrossrefPubMedGoogle Scholar
  • 137 Sainz J, Pérez E, Hassan L. , et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007; 68 (01) 41-50
    CrossrefPubMedGoogle Scholar
  • 138 Zaas AK, Liao G, Chien JW. , et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008; 4 (06) e1000101
    CrossrefPubMedGoogle Scholar
  • 139 Thompson III GR, Patterson TF. Pulmonary aspergillosis. Semin Respir Crit Care Med 2008; 29 (02) 103-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 140 Krenke R, Grabczak EM. Tracheobronchial manifestations of Aspergillus infections. ScientificWorldJournal 2011; 11: 2310-2329
    CrossrefPubMedGoogle Scholar
  • 141 Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 1994; 105 (05) 1314-1323
    CrossrefPubMedGoogle Scholar
  • 142 Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123 (03) 800-808
    CrossrefPubMedGoogle Scholar
  • 143 Lortholary O, Meyohas MC, Dupont B. , et al; French Cooperative Study Group on Aspergillosis in AIDS. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. Am J Med 1993; 95 (02) 177-187
    CrossrefPubMedGoogle Scholar
  • 144 Greene RE, Schlamm HT, Oestmann JW. , et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44 (03) 373-379
    CrossrefPubMedGoogle Scholar
  • 145 Patterson TF, Thompson III GR, Denning DW. , et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63 (04) e1-e60
    CrossrefPubMedGoogle Scholar
  • 146 Ullmann AJ, Aguado JM, Arikan-Akdagli S. , et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018; 24 (Suppl. 01) e1-e38
    CrossrefPubMedGoogle Scholar
  • 147 Bergeron A, Porcher R, Sulahian A. , et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012; 119 (08) 1831-1837 , quiz 1956
    CrossrefPubMedGoogle Scholar
  • 148 Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerhouni EA, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987; 92 (01) 95-99
    CrossrefPubMedGoogle Scholar
  • 149 Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001; 7 (Suppl. 02) 54-61
    CrossrefPubMedGoogle Scholar
  • 150 Prasad A, Agarwal K, Deepak D, Atwal SS. Pulmonary aspergillosis: what CT can offer before it is too late!. J Clin Diagn Res 2016; 10 (04) TE01-TE05
    PubMedGoogle Scholar
  • 151 Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001; 21 (04) 825-837
    CrossrefPubMedGoogle Scholar
  • 152 De Pauw B, Walsh TJ, Donnelly JP. , et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
    CrossrefPubMedGoogle Scholar
  • 153 Muñoz P, Vena A, Cerón I. , et al; PROMULGA Project Group. Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. J Heart Lung Transplant 2014; 33 (10) 1034-1040
    CrossrefPubMedGoogle Scholar
  • 154 Jin J, Wu D, Liu Y. , et al. Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data. BMC Infect Dis 2019; 19 (01) 471
    CrossrefPubMedGoogle Scholar
  • 155 Gazzoni FF, Hochhegger B, Severo LC. , et al. High-resolution computed tomographic findings of Aspergillus infection in lung transplant patients. Eur J Radiol 2014; 83 (01) 79-83
    CrossrefPubMedGoogle Scholar
  • 156 Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 2008; 46 (01) 23-29
    CrossrefPubMedGoogle Scholar
  • 157 Ankrah AO, Span LFR, Klein HC. , et al. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. Eur J Nucl Med Mol Imaging 2019; 46 (01) 174-183
    CrossrefPubMedGoogle Scholar
  • 158 Hot A, Maunoury C, Poiree S. , et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011; 17 (03) 409-417
    CrossrefPubMedGoogle Scholar
  • 159 Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006; 82 (03) 1016-1020
    CrossrefPubMedGoogle Scholar
  • 160 Leroy-Freschini B, Treglia G, Argemi X. , et al. 18F-FDG PET/CT for invasive fungal infection in immunocompromised patients. QJM 2018; 111 (09) 613-622
    CrossrefPubMedGoogle Scholar
  • 161 Camus V, Edet-Sanson A, Bubenheim M. , et al. 18F-FDG-PET/CT imaging in patients with febrile neutropenia and haematological malignancies. Anticancer Res 2015; 35 (05) 2999-3005
    PubMedGoogle Scholar
  • 162 Kim JY, Yoo JW, Oh M. , et al. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J Comput Assist Tomogr 2013; 37 (04) 596-601
    CrossrefPubMedGoogle Scholar
  • 163 Rolle AM, Hasenberg M, Thornton CR. , et al. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci U S A 2016; 113 (08) E1026-E1033
    CrossrefPubMedGoogle Scholar
  • 164 Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011; 117 (15) 3424-3433
    CrossrefPubMedGoogle Scholar
  • 165 Hardak E, Avivi I, Berkun L. , et al. Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. Infection 2016; 44 (04) 491-497
    CrossrefPubMedGoogle Scholar
  • 166 Lass-Flörl C. How to make a fast diagnosis in invasive aspergillosis. Med Mycol 2019; 57 (Suppl. 02) S155-S160
    CrossrefPubMedGoogle Scholar
  • 167 Atalay A, Koc AN, Suel A. , et al. Conventional morphology versus PCR sequencing, rep-PCR, and MALDI-TOF-MS for identification of clinical Aspergillus isolates collected over a 2-year period in a university hospital at Kayseri, Turkey. J Clin Lab Anal 2016; 30 (05) 745-750
    CrossrefPubMedGoogle Scholar
  • 168 Miceli MH, Maertens J. Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive aspergillosis. Semin Respir Crit Care Med 2015; 36 (05) 650-661
    Article in Thieme ConnectPubMedGoogle Scholar
  • 169 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42 (10) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 170 Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. ; European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47 (06) 846-854
    CrossrefPubMedGoogle Scholar
  • 171 Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138 (04) 817-824
    CrossrefPubMedGoogle Scholar
  • 172 Zou M, Tang L, Zhao S. , et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012; 7 (08) e43347
    CrossrefPubMedGoogle Scholar
  • 173 de Heer K, Gerritsen MG, Visser CE, Leeflang MM. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2019; 5: CD012399
    PubMedGoogle Scholar
  • 174 Richardson MD, Page ID. Aspergillus serology: have we arrived yet?. Med Mycol 2017; 55 (01) 48-55
    CrossrefPubMedGoogle Scholar
  • 175 Kappe R, Rimek D. Antibody detection in patients with invasive aspergillosis [in German]. Mycoses 2004; 47 (Suppl. 01) 55-59
    CrossrefPubMedGoogle Scholar
  • 176 Patterson TF, Donnelly JP. New concepts in diagnostics for invasive mycoses: non-culture-based methodologies. J Fungi (Basel) 2019; 5 (01) 5
    PubMedGoogle Scholar
  • 177 Barnes RA, White PL, Morton CO. , et al. Diagnosis of aspergillosis by PCR: clinical considerations and technical tips. Med Mycol 2018; 56 (Suppl. 01) 60-72
    CrossrefPubMedGoogle Scholar
  • 178 White PL, Barnes RA, Springer J. , et al; EAPCRI. Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR initiative. J Clin Microbiol 2015; 53 (09) 2832-2837
    CrossrefPubMedGoogle Scholar
  • 179 Rath PM, Steinmann J. Overview of commercially available PCR assays for the detection of Aspergillus spp. DNA in patient samples. Front Microbiol 2018; 9: 740
    CrossrefPubMedGoogle Scholar
  • 180 Chong GL, van de Sande WW, Dingemans GJ. , et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol 2015; 53 (03) 868-874
    CrossrefPubMedGoogle Scholar
  • 181 Denis J, Forouzanfar F, Herbrecht R. , et al. Evaluation of two commercial real-time PCR kits for Aspergillus DNA detection in bronchoalveolar lavage fluid in patients with invasive pulmonary aspergillosis. J Mol Diagn 2018; 20 (03) 298-306
    CrossrefPubMedGoogle Scholar
  • 182 Cruciani M, Mengoli C, Barnes R. , et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev 2019; 9: CD009551
    PubMedGoogle Scholar
  • 183 Torelli R, Sanguinetti M, Moody A. , et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49 (12) 4273-4278
    CrossrefPubMedGoogle Scholar
  • 184 Moura S, Cerqueira L, Almeida A. Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. Eur J Clin Microbiol Infect Dis 2018; 37 (08) 1393-1403
    CrossrefPubMedGoogle Scholar
  • 185 Dannaoui E, Gabriel F, Gaboyard M. , et al. Molecular diagnosis of invasive aspergillosis and detection of azole resistance by a newly commercialized PCR kit. J Clin Microbiol 2017; 55 (11) 3210-3218
    CrossrefPubMedGoogle Scholar
  • 186 Chong GM, van der Beek MT, von dem Borne PA. , et al. PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius Assay® in 201 patients with haematological disease suspected for invasive aspergillosis. J Antimicrob Chemother 2016; 71 (12) 3528-3535
    CrossrefPubMedGoogle Scholar
  • 187 White PL, Posso RB, Barnes RA. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs directly from plasma samples. J Clin Microbiol 2017; 55 (08) 2356-2366
    CrossrefPubMedGoogle Scholar
  • 188 Paterson PJ, Seaton S, McLaughlin J, Kibbler CC. Development of molecular methods for the identification of aspergillus and emerging moulds in paraffin wax embedded tissue sections. Mol Pathol 2003; 56 (06) 368-370
    CrossrefPubMedGoogle Scholar
  • 189 Shinozaki M, Tochigi N, Sadamoto S, Yamagata Murayama S, Wakayama M, Nemoto T. Histopathological diagnosis of invasive fungal infections in formalin-fixed and paraffin-embedded tissues in conjunction with molecular methods. Med Mycol J 2018; 59 (01) E7-E18
    PubMedGoogle Scholar
  • 190 Gade L, Hurst S, Balajee SA, Lockhart SR, Litvintseva AP. Detection of mucormycetes and other pathogenic fungi in formalin fixed paraffin embedded and fresh tissues using the extended region of 28S rDNA. Med Mycol 2017; 55 (04) 385-395
    PubMedGoogle Scholar
  • 191 Salehi E, Hedayati MT, Zoll J. , et al. Discrimination of aspergillosis, mucormycosis, fusariosis, and scedosporiosis in formalin-fixed paraffin-embedded tissue specimens by use of multiple real-time quantitative PCR assays. J Clin Microbiol 2016; 54 (11) 2798-2803
    CrossrefPubMedGoogle Scholar
  • 192 Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008; 15 (07) 1095-1105
    CrossrefPubMedGoogle Scholar
  • 193 Arvanitis M, Mylonakis E. Diagnosis of invasive aspergillosis: recent developments and ongoing challenges. Eur J Clin Invest 2015; 45 (06) 646-652
    CrossrefPubMedGoogle Scholar
  • 194 Jenks JD, Mehta SR, Taplitz R, Aslam S, Reed SL, Hoenigl M. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test in bronchoalveolar lavage. Mycoses 2019; 62 (03) 230-236
    CrossrefPubMedGoogle Scholar
  • 195 Johnson GL, Sarker SJ, Nannini F. , et al. Aspergillus-specific lateral-flow device and real-time PCR testing of bronchoalveolar lavage fluid: a combination biomarker approach for clinical diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2015; 53 (07) 2103-2108
    CrossrefPubMedGoogle Scholar
  • 196 Mercier T, Schauwvlieghe A, de Kort E. , et al. Diagnosing invasive pulmonary aspergillosis in hematology patients: a retrospective multicenter evaluation of a novel lateral flow device. J Clin Microbiol 2019; 57 (04) e01913-e01918
    PubMedGoogle Scholar
  • 197 Hoenigl M, Eigl S, Heldt S, Duettmann W, Thornton C, Prattes J. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Mycoses 2018; 61 (01) 40-43
    CrossrefPubMedGoogle Scholar
  • 198 von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62 (06) 341-347
    CrossrefPubMedGoogle Scholar
  • 199 Herbrecht R, Patterson TF, Slavin MA. , et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015; 60 (05) 713-720
    CrossrefPubMedGoogle Scholar
  • 200 Cornely OA, Maertens J, Bresnik M. , et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54 (05) e449-e455
    CrossrefPubMedGoogle Scholar
  • 201 Gregg KS, Kauffman CA. Invasive aspergillosis: epidemiology, clinical aspects, and treatment. Semin Respir Crit Care Med 2015; 36 (05) 662-672
    Article in Thieme ConnectPubMedGoogle Scholar
  • 202 Denning DW, Lee JY, Hostetler JS. , et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97 (02) 135-144
    CrossrefPubMedGoogle Scholar
  • 203 Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7 (Suppl. 02) 25-31
    PubMedGoogle Scholar
  • 204 Maertens JA, Raad II, Marr KA. , et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387 (10020): 760-769
    CrossrefPubMedGoogle Scholar
  • 205 Marr KA, Schlamm HT, Herbrecht R. , et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162 (02) 81-89
    CrossrefPubMedGoogle Scholar
  • 206 Herbrecht R, Denning DW, Patterson TF. , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (06) 408-415
    CrossrefPubMedGoogle Scholar
  • 207 Cornely OA, Maertens J, Bresnik M. , et al; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44 (10) 1289-1297
    CrossrefPubMedGoogle Scholar
  • 208 Viscoli C, Herbrecht R, Akan H. , et al; Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64 (06) 1274-1281
    CrossrefPubMedGoogle Scholar
  • 209 Herbrecht R, Maertens J, Baila L. , et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer Study. Bone Marrow Transplant 2010; 45 (07) 1227-1233
    CrossrefPubMedGoogle Scholar
  • 210 Denning DW, Ribaud P, Milpied N. , et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34 (05) 563-571
    CrossrefPubMedGoogle Scholar
  • 211 Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112 (10) 2309-2312
    CrossrefPubMedGoogle Scholar
  • 212 Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40 (Suppl. 06) S392-S400
    CrossrefPubMedGoogle Scholar
  • 213 Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005; 24 (02) 167-174
    CrossrefPubMedGoogle Scholar
  • 214 Herbrecht R, Auvrignon A, Andrès E. , et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001; 20 (02) 77-82
    PubMedGoogle Scholar
  • 215 Tissot F, Agrawal S, Pagano L. , et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102 (03) 433-444
    CrossrefPubMedGoogle Scholar
  • 216 Bowden R, Chandrasekar P, White MH. , et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35 (04) 359-366
    CrossrefPubMedGoogle Scholar
  • 217 Rijnders BJ, Cornelissen JJ, Slobbe L. , et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46 (09) 1401-1408
    CrossrefPubMedGoogle Scholar
  • 218 Schwartz S, Behre G, Heinemann V. , et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93 (11) 3654-3661
    PubMedGoogle Scholar
  • 219 Minari A, Husni R, Avery RK. , et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4 (04) 195-200
    CrossrefPubMedGoogle Scholar
  • 220 Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8 (01) 13-20
    CrossrefPubMedGoogle Scholar
  • 221 Xia D, Sun WK, Tan MM. , et al. Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: a meta-analysis. Int J Infect Dis 2015; 30: 78-84
    CrossrefPubMedGoogle Scholar
  • 222 Palmer SM, Drew RH, Whitehouse JD. , et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72 (03) 545-548
    CrossrefPubMedGoogle Scholar
  • 223 Maertens J, Raad I, Petrikkos G. , et al; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39 (11) 1563-1571
    CrossrefPubMedGoogle Scholar
  • 224 Aliff TB, Maslak PG, Jurcic JG. , et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97 (04) 1025-1032
    CrossrefPubMedGoogle Scholar
  • 225 Kontoyiannis DP, Hachem R, Lewis RE. , et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98 (02) 292-299
    CrossrefPubMedGoogle Scholar
  • 226 Singh N, Limaye AP, Forrest G. , et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81 (03) 320-326
    CrossrefPubMedGoogle Scholar
  • 227 Caillot D, Thiébaut A, Herbrecht R. , et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110 (12) 2740-2746
    CrossrefPubMedGoogle Scholar
  • 228 Cesaro S, Giacchino M, Locatelli F. , et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007; 7: 28
    CrossrefPubMedGoogle Scholar
  • 229 Aruanno M, Glampedakis E, Lamoth F. Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside. Antimicrob Agents Chemother 2019; 63 (08) 63
    CrossrefPubMedGoogle Scholar
  • 230 van Burik JA, Ratanatharathorn V, Stepan DE. , et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39 (10) 1407-1416
    CrossrefPubMedGoogle Scholar
  • 231 Herbrecht R, Kuessner D, Pooley N, Posthumus J, Escrig C. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. Curr Med Res Opin 2018; 34 (12) 2187-2195
    CrossrefPubMedGoogle Scholar
  • 232 Marty FM, Ostrosky-Zeichner L, Cornely OA. , et al; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16 (07) 828-837
    CrossrefPubMedGoogle Scholar
  • 233 Leclerc E, Combarel D, Uzunov M, Leblond V, Funck-Brentano C, Zahr N. Prevention of invasive Aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies. Sci Rep 2018; 8 (01) 1681
    CrossrefPubMedGoogle Scholar
  • 234 Walsh TJ, Raad I, Patterson TF. , et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44 (01) 2-12
    CrossrefPubMedGoogle Scholar
  • 235 Martínez-Casanova J, Carballo N, Luque S, Sorli L, Grau S. Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis. Infect Drug Resist 2018; 11: 317-321
    CrossrefPubMedGoogle Scholar
  • 236 Greenberg RN, Mullane K, van Burik JAH. , et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50 (01) 126-133
    CrossrefPubMedGoogle Scholar
  • 237 van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42 (07) e61-e65
    CrossrefPubMedGoogle Scholar
  • 238 Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist 2011; 16 (07) 1049-1060
    CrossrefPubMedGoogle Scholar
  • 239 Nivoix Y, Velten M, Letscher-Bru V. , et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47 (09) 1176-1184
    CrossrefPubMedGoogle Scholar
  • 240 Maertens JA, Girmenia C, Brüggemann RJ. , et al; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 2018; 73 (12) 3221-3230
    PubMedGoogle Scholar
  • 241 Donnelly JP, Chen S, Kauffman C. , et al, Revision and Update of the Consensus Definitions of Invasive Fungal Infections from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium, Clin Infect Dis, 2019, ahead of print
    PubMed